SENS Headlines
Aspen closes circa €3,400, 000,000 equivalent syndicated facilities


(Incorporated in the Republic of South Africa) (“Aspen Holdings”)

Registration number: 1985/0002935/06

Share code: APN

ISIN: ZAE000066692

and its subsidiaries (collectively “Aspen” or “the Group”)


Aspen Holdings is pleased to announce the successful closing of multi-currency syndicated facilities
equivalent to approximately EUR 3,400,000,000 (the “Facilities”) for Aspen Holdings’ wholly owned
subsidiaries Aspen Finance (Pty) Ltd, Pharmacare Limited t/a Aspen Pharmacare and Aspen Asia Pacific
Pty Ltd on 16th May 2018.

The Facilities were structured across EUR, ZAR and AUD term and revolving credit facilities with tenors
of 2 to 4 years with a one-year extension option. All Facilities were consolidated into a single facility
agreement with lenders ranking pari-passu.

The aggregate Facilities across EUR, ZAR and AUD were more than 70% oversubscribed, allowing
Aspen to upsize the EUR Facilities to EUR 2,650,000,000 while still providing significant scale back.

The successful conclusion of these funding arrangements reflects the confidence of lenders in the
Aspen business case.

MUFG Bank, Ltd. and Nedbank Limited (acting through its Nedbank Corporate and Investment Banking
division) acted as Global Coordinators, Initial Mandated Lead Arrangers and Bookrunners for this
transaction. MUFG Bank, Ltd. acted as the EUR and AUD Coordinator, Arranger and Bookrunner as
well as Documentation Agent. Nedbank acted as EUR and ZAR Coordinator, Arranger and Bookrunner
as well as Publicity Agent.

Twenty-eight lenders committed to the Facilities from across the United States of America, Europe,
Africa, Australia and Asia, comprising existing core relationship banks, as well as a number of new

Details of the Facilities are as follows:

EUR Facilities

Borrower:           Aspen Finance (Pty) Ltd

Facilities:         EUR 1,000,000,000 2 year term facility

                    EUR 500,000,000 4 year term facility

                    EUR 1,150,000,000 4 year revolving credit facility

Purpose:            Refinancing the indebtedness of the Group and general corporate purposes
ZAR Facilities

Borrower:           Pharmacare Limited

Facilities:         ZAR 6,000,000,000 4 year term facility

                    ZAR 2,000,000,000 4 year revolving credit facility

Purpose:            Refinancing the indebtedness of the Group and general corporate purposes

AUD Facilities

Borrower:           Aspen Asia Pacific Pty Ltd

Facilities:         AUD 350,000,000 4 year revolving credit facility

Purpose:            Refinancing the indebtedness of the Group and general corporate purposes

The Facilities are guaranteed by Aspen Pharmacare Holdings Limited, Pharmacare Limited, Aspen
Global Incorporated, Aspen Asia Pacific Pty Ltd, Aspen Finance (Pty) Ltd, Aspen Nutritionals Australia
Pty Ltd, Aspen Pharmacare Australia Pty Ltd, Aspen Pharma Pty Ltd, Orphan Holdings Pty Ltd.


Initial Mandated Lead Arrangers and Bookrunners

MUFG Bank, Ltd.

Nedbank Limited (acting through its Nedbank Corporate and Investment Banking division)

Mandated Lead Arrangers and Bookrunners:

ABSA Bank Limited
Bank of America Merrill Lynch International Limited
BNP Paribas
Citi Bank N.A, DIFC Branch
FirstRand Bank Limited (acting through its Rand Merchant Bank division)
Investec Bank Limited
Mizuho Bank Limited
JPMorgan Chase Bank, N.A., London Branch
Standard Chartered Bank
Standard Finance (Isle of Man) Limited
The Standard Bank of South Africa Limited
Sumitomo Mitsui Banking Corporation Europe Limited

Mandated Lead Arrangers:

Intesa Sanpaolo Bank Luxembourg S.A.
MMI Group Limited
National Australia Bank Limited
Various entities within the Sanlam Investment Group

Lead Arrangers:

China Construction Bank Corporation, Johannesburg Branch
Commonwealth Bank of Australia
Industrial and Commercial Bank of China (Thai) Public Company Limited


AfrAsia Bank Limited

CaixaBank, S.A.
Deutsche Bank Luxembourg S.A.

The Governor and Company of the Bank of Ireland

The Mauritius Commercial Bank Limited

Westpac Banking Corporation

17 May 2018

Investec Bank Limited
About Aspen

Aspen is a leading global player in specialty and branded pharmaceuticals with an extensive basket of
products that provide treatment for a broad spectrum of acute and chronic conditions experienced
through all stages of life. Aspen benefits the lives of patients using its products in more than 150

Aspen has a strong presence in both emerging and developed countries. Its emerging market footprint
includes Sub-Saharan Africa (where it is the largest pharmaceutical company), Latin America, South
East Asia, Eastern Europe and the Commonwealth of Independent States, comprising Russia and the
former Soviet Republics. From a developed world perspective Aspen is one of the leading
pharmaceutical companies in Australia and has a presence in a number of other developed countries,
most notably in Western Europe.

Aspen operates with an established business presence in approximately 50 countries spanning 6
continents and employs more than 10,000 people. The Group operates 25 manufacturing facilities
across 18 sites. Aspen holds international manufacturing approvals from some of the most stringent
global regulatory agencies including the FDA, TGA and EMA. Aspen’s manufacturing capabilities are
scalable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-
solids, steriles, biologicals, APIs and INs.

Aspen, with a market cap of c. $10 billion, is the largest pharmaceutical company listed on the JSE
Limited (share code: APN) and ranks amongst the top 30 listed companies on this exchange. For more
information visit:

Date: 17/05/2018 12:57:00 
Supplied by
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.